CTOs on the Move

Celsis International Plc

www.celsis.com

 
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas, rapid detection, analytical and
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.celsis.com
  • 600 W Chicago Ave
    Chicago, IL USA 60654
  • Phone: 312.476.1200

Executives

Name Title Contact Details

Similar Companies

Zwanger Pesiri Radiology

Zwanger Pesiri Radiology is a Massapequa, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lerner Research Institute

Cleveland Clinic`s rich history includes continuous emphasis on research and innovation. In 1921, the founders stated their commitment not only to treating disease and educating the next generations of healers, but also to researching the causes of disease. They realized that understanding the biological basis of disease is necessary to developing new diagnostics and therapeutics.

Lucigen

Located in Middleton, WI, Lucigen delivers innovative products and services to life scientists and manufacturers for the most pressing challenges in research and molecular diagnostics. With a focus on quality, ease-of-use, and affordability, Lucigen strives to make our customer’s research, manufacturing and diagnostic testing successful and cost-efficient.

Fortis Life Sciences

Fortis Life Sciences offers word-class reagents, tools, materials, and custom services for our research, diagnostic and therapeutic customers. Learn more here.

Makindus

Makindus is a privately-held, specialty pharmaceutical development company focused on ophthalmology and rare diseases. The Company`s lead product candidate is MI-100, a novel ophthalmic formulation of a legacy compound being developed for Stargardt disease, a rare form of juvenile macular degeneration that occurs in approximately 1 in 10,000 individuals. Makindus has met with the FDA and EMA, and is in the final stages of planning a Phase 3 clinical trial program. The Company is seeking partners and additional sources of funding and collaboration for the development program of MI-100 for Stargardt disease.